Expression of estrogen receptor-β in normal mammary and tumor tissues: Is it protective in breast carcinogenesis?

Byeong Woo Park; Ki Suk Kim; Min Kyu Heo; Seung Sang Ko; Soon Won Hong; Woo Ick Yang; Joo Hang Kim; Gwi Eon Kim; Kyong Sik Lee

doi:10.1023/A:1024406223619

Expression of estrogen receptor-β in normal mammary and tumor tissues: Is it protective in breast carcinogenesis?

Byeong Woo Park, Ki Suk Kim, Min Kyu Heo, Seung Sang Ko, Soon Won Hong, Woo Ick Yang, Joo Hang Kim, Gwi Eon Kim, Kyong Sik Lee

Department of Surgery

Research output: Contribution to journal › Article › peer-review

61 Citations (Scopus)

Abstract

Using messenger RNA (mRNA) in situ hybridization, we investigated estrogen receptor-β (ERβ) mRNA levels in normal mammary, benign breast tumor (BBT), breast cancer (BC), and metastatic lymph node tissues to verify the role of ERβ in BC development and progression. ERβ expression was significantly decreased in BC and metastatic lymph node tissues compared with normal mammary and BBT tissues (p < 0.01). The intensity and extent of ERβ mRNA signals were also significantly lower in BC and metastatic lymph node tissues than in the normal mammary and BBT tissues (p < 0.01). An inverse relationship was found between ERβ mRNA level and both histologic grade (p = 0.091) and progesterone receptor expression (p = 0.052) with marginal significance, but no significant association was noted between ERβ expression in cancer tissues and the other clinico-pathologic data. The 3-year distant relapse-free survival probability was found to be independent of ERβ expression. Collectively, ERβ mRNA decreases in the process of BC development, but seems to be associated with poor differentiation.

Original language	English
Pages (from-to)	79-85
Number of pages	7
Journal	Breast Cancer Research and Treatment
Volume	80
Issue number	1
DOIs	https://doi.org/10.1023/A:1024406223619
Publication status	Published - 2003 Jul

Bibliographical note

Funding Information:
This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, and in part by a grant-in-aid from Dong-A Pharmaceutical Co. Ltd., Cheil Jedang Corporation and Aventis Pharmaceutical Co. Ltd., South Korea. This work was presented at the 25th San Antonio Breast Cancer Symposium as a poster.

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1023/A:1024406223619

Cite this

@article{6a2ad9d894a347918e30a9730fd4853e,

title = "Expression of estrogen receptor-β in normal mammary and tumor tissues: Is it protective in breast carcinogenesis?",

abstract = "Using messenger RNA (mRNA) in situ hybridization, we investigated estrogen receptor-β (ERβ) mRNA levels in normal mammary, benign breast tumor (BBT), breast cancer (BC), and metastatic lymph node tissues to verify the role of ERβ in BC development and progression. ERβ expression was significantly decreased in BC and metastatic lymph node tissues compared with normal mammary and BBT tissues (p < 0.01). The intensity and extent of ERβ mRNA signals were also significantly lower in BC and metastatic lymph node tissues than in the normal mammary and BBT tissues (p < 0.01). An inverse relationship was found between ERβ mRNA level and both histologic grade (p = 0.091) and progesterone receptor expression (p = 0.052) with marginal significance, but no significant association was noted between ERβ expression in cancer tissues and the other clinico-pathologic data. The 3-year distant relapse-free survival probability was found to be independent of ERβ expression. Collectively, ERβ mRNA decreases in the process of BC development, but seems to be associated with poor differentiation.",

author = "Park, {Byeong Woo} and Kim, {Ki Suk} and Heo, {Min Kyu} and Ko, {Seung Sang} and Hong, {Soon Won} and Yang, {Woo Ick} and Kim, {Joo Hang} and Kim, {Gwi Eon} and Lee, {Kyong Sik}",

note = "Funding Information: This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, and in part by a grant-in-aid from Dong-A Pharmaceutical Co. Ltd., Cheil Jedang Corporation and Aventis Pharmaceutical Co. Ltd., South Korea. This work was presented at the 25th San Antonio Breast Cancer Symposium as a poster.",

year = "2003",

month = jul,

doi = "10.1023/A:1024406223619",

language = "English",

volume = "80",

pages = "79--85",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer New York",

number = "1",

}

TY - JOUR

T1 - Expression of estrogen receptor-β in normal mammary and tumor tissues

T2 - Is it protective in breast carcinogenesis?

AU - Park, Byeong Woo

AU - Kim, Ki Suk

AU - Heo, Min Kyu

AU - Ko, Seung Sang

AU - Hong, Soon Won

AU - Yang, Woo Ick

AU - Kim, Joo Hang

AU - Kim, Gwi Eon

AU - Lee, Kyong Sik

N1 - Funding Information: This work was supported by the Brain Korea 21 Project for Medical Science, Yonsei University, and in part by a grant-in-aid from Dong-A Pharmaceutical Co. Ltd., Cheil Jedang Corporation and Aventis Pharmaceutical Co. Ltd., South Korea. This work was presented at the 25th San Antonio Breast Cancer Symposium as a poster.

PY - 2003/7

Y1 - 2003/7

N2 - Using messenger RNA (mRNA) in situ hybridization, we investigated estrogen receptor-β (ERβ) mRNA levels in normal mammary, benign breast tumor (BBT), breast cancer (BC), and metastatic lymph node tissues to verify the role of ERβ in BC development and progression. ERβ expression was significantly decreased in BC and metastatic lymph node tissues compared with normal mammary and BBT tissues (p < 0.01). The intensity and extent of ERβ mRNA signals were also significantly lower in BC and metastatic lymph node tissues than in the normal mammary and BBT tissues (p < 0.01). An inverse relationship was found between ERβ mRNA level and both histologic grade (p = 0.091) and progesterone receptor expression (p = 0.052) with marginal significance, but no significant association was noted between ERβ expression in cancer tissues and the other clinico-pathologic data. The 3-year distant relapse-free survival probability was found to be independent of ERβ expression. Collectively, ERβ mRNA decreases in the process of BC development, but seems to be associated with poor differentiation.

AB - Using messenger RNA (mRNA) in situ hybridization, we investigated estrogen receptor-β (ERβ) mRNA levels in normal mammary, benign breast tumor (BBT), breast cancer (BC), and metastatic lymph node tissues to verify the role of ERβ in BC development and progression. ERβ expression was significantly decreased in BC and metastatic lymph node tissues compared with normal mammary and BBT tissues (p < 0.01). The intensity and extent of ERβ mRNA signals were also significantly lower in BC and metastatic lymph node tissues than in the normal mammary and BBT tissues (p < 0.01). An inverse relationship was found between ERβ mRNA level and both histologic grade (p = 0.091) and progesterone receptor expression (p = 0.052) with marginal significance, but no significant association was noted between ERβ expression in cancer tissues and the other clinico-pathologic data. The 3-year distant relapse-free survival probability was found to be independent of ERβ expression. Collectively, ERβ mRNA decreases in the process of BC development, but seems to be associated with poor differentiation.

UR - http://www.scopus.com/inward/record.url?scp=0038160964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038160964&partnerID=8YFLogxK

U2 - 10.1023/A:1024406223619

DO - 10.1023/A:1024406223619

M3 - Article

C2 - 12889601

AN - SCOPUS:0038160964

SN - 0167-6806

VL - 80

SP - 79

EP - 85

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 1

ER -

Expression of estrogen receptor-β in normal mammary and tumor tissues: Is it protective in breast carcinogenesis?

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this